Marcus Almärid
Analyst, DNB Carnegie
Replay available
Ependion AB (STO: EPEN) Q2 2025 earnings conference call, held 2025-07-15. Replay captured from the company's public earnings webcast.

Analyst, DNB Carnegie
Analyst, Red Eye AB
CFO
CEO
Thank you very much. Welcome, everybody, to the Appendion Quarter 2 call. The headline for our report this time is Increased order intake and improved earnings in an uncertain market. So, we present in the call is, as usual, myself, Jenny Sködahl, today in Västerås. And with me, I have Joakim Laurén located in Malmö today. And as usual, the agenda looks like this. I will give a general business update first, then Joakim will dig a little bit deeper into the numbers, some concluding notes and outlook from myself, and then we open up for questions and answers. so let's dive right into it so the overall business update for the quarter well i think we all see that the market is still affected by the uncertainty regarding the conditions for international trade giving a slight hesitation among our customers in terms of investments and so on on the other hand of course the world has not come to a stop so there's a lot of activity still going on in in our markets but but still a little bit uncertain market conditions. However, in the quarter, the order intake for Appendion increased by 16%, where we see growth in both business entities, Vestamo at 22% growth and Bayer Electronics at 5%. And as you probably know, we have closed the Velotech deal in the quarter and this company was added as from June and the organic order intake then comes out at 11%. Sales-wise, our sales are still a little bit affected by the somewhat lower order intake that we have seen in end of 2024 and beginning of this year, so minus 5%, with a pretty strong comparison quarter. And there are also some phase-out effects for Bayer Electronics, because as you know, we have been cleaning up our product portfolio We have phased out the display solutions volumes as part of the more focused strategy for Bay El...